Background: The rapid diffusion of Novel Psychoactive Substances (NPS) constitutes an important challenge in terms of public health and a novelty in clinical settings, where these compounds may lead to erratic symptoms, unascertained effects and multi-intoxication scenarios, especially in emergency situations. The number of NPS available on the illicit drug market is astonishing: official reports suggest the appearance of a new drug every week. NPS may be enlisted in many different families such as synthetic phenethylamines, tryptamines, cathinones, piperazines, ketamine-like compounds, cannabimimetics and other plant-derived, medical products and derivatives. Therefore, healthcare services and professionals are often called to face this un...
Introduction: The abuse of New Psychoactive Substances (NPS) has been a major issue since the 1990s,...
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article dist...
Objectives: The recent emergence of new psychoactive compounds (NPS) has raised prominent challenges...
INTRODUCTION: Novel psychoactive substances (NPS; a.k.a. 'legal highs' or 'smart drugs') are adverti...
In the last decade, the trend of drug consumption has completely changed, and several new psychoacti...
Submitted 24 November 2018, Revised 18 June 2019, Accepted 26 June 2019, Published online 22 July 20...
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article dist...
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions f...
This is an open access article distributed under the Creative Commons Attribution License which perm...
In parallel with a decrease/stabilization in the use of internationally controlled drugs, the market...
© 2017 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Deligiann...
This is the peer reviewed version of the following article: Pierluigi Simonato, Grancesco S. Bersani...
Use of new psychoactive substances (NPS) across Europe remains a public health challenge. The study ...
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europ...
Introduction: The abuse of New Psychoactive Substances (NPS) has been a major issue since the 1990s,...
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article dist...
Objectives: The recent emergence of new psychoactive compounds (NPS) has raised prominent challenges...
INTRODUCTION: Novel psychoactive substances (NPS; a.k.a. 'legal highs' or 'smart drugs') are adverti...
In the last decade, the trend of drug consumption has completely changed, and several new psychoacti...
Submitted 24 November 2018, Revised 18 June 2019, Accepted 26 June 2019, Published online 22 July 20...
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article dist...
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions f...
This is an open access article distributed under the Creative Commons Attribution License which perm...
In parallel with a decrease/stabilization in the use of internationally controlled drugs, the market...
© 2017 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Deligiann...
This is the peer reviewed version of the following article: Pierluigi Simonato, Grancesco S. Bersani...
Use of new psychoactive substances (NPS) across Europe remains a public health challenge. The study ...
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europ...
Introduction: The abuse of New Psychoactive Substances (NPS) has been a major issue since the 1990s,...
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article dist...